Investigating the treatment of ovarian cancer by optimized measles vaccine

Phase 1

Recruiting

• Conditions: Ovarian cancer.; Malignant neoplasm of ovary

• Registration Number: IRCT20230903059342N2
• Lead Sponsor: Kian Gen Azma Company

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 15

Inclusion Criteria

Confirmation of the patient's ovarian cancer by a gynecologist
Diagnosis of disease as drug resistance
Patient age 18 to 70
Absence of pregnancy.
The Karnofsky performance score (KPS) of the patient is more than 50% (the patient is not disabled and does not need special assistance and care).
The ability to understand and sign the consent form by the patient and one of these cases: the patient's spouse, parent or guardian.
Proper functioning of liver, kidney and bone marrow
Complying with all protocol steps including sample submission and returning to the clinical study site for subsequent visits
Absence of autoimmune diseases or diseases of the immune system

Exclusion Criteria

Life-threatening acute infection
Absence of any previous record that describes the doctor's treatment and orders were nor followed by patient.
Using drugs that weaken the immune system
Affected by any diseases that disturbs the immune system
Having any previous record of organ transplantation
Allergy to measles vaccine
pregnancy
Using other investigational treatments at the same time
Being effected by other cancers

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fever. Timepoint: Hourly in the first 24 hours and then daily up to 7 days. Method of measurement: Thermometer.;Examining changes in the patient's heart condition. Timepoint: Hourly after the start of treatment for up to 7 days. Method of measurement: Electrocardiogram.;Examining changes in the patient's breathing status. Timepoint: Hourly in the first 24 hours and then daily up to 7 days. Method of measurement: pulse oximeter.;Examining the amount of ca 125 cancer antigen in the blood. Timepoint: Weekly until 3 months after the end of treatment. Method of measurement: Blood test.;Examination of tumors of the abdominal cavity. Timepoint: Weekly until 3 months after the end of treatment. Method of measurement: Sonography.